Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major.
Experimental cutaneous leishmaniasis is a useful model in studying the mechanism regulating immune responses between T helper type 1 (Th1) and Th2. Mice susceptible to Leishmania major infection such as BALB/c (H-2(d)) are associated with the induction of the disease-promoting Th2 response, while the resistant mice such as DBA/2 (H-2(d)) develop the protective Th1 response. To understand the induction mechanism of Th1 and Th2 responses, it is necessary to establish an immunization scheme by which the induction of each Th response can be easily and experimentally controlled. Adjuvants are known to enhance the immune responses through the combined effect of several factors: prolonged release of antigen, migration of cells, mitogenic effect and so forth. When the genetically resistant DBA/2 mice were immunized twice with soluble leishmanial antigen (SLA), emulsified in incomplete Freund's adjuvant (IFA) before L. major inoculation, these mice mounted a Th2 cell response and suffered from progressive infection. While IL-4 and IL-13 were upregulated early after the infection in both healer and non-healer groups of mice, IL-5 and IL-10 were upregulated only in non-healer mice. From these results, IL-5 and IL-10 appear to have an important role, at least in the early phases of the infection, rather than IL-4 and IL-13 in establishing the disease-promoting Th2 response in leishmaniasis. Further, IL-9 was found to be expressed in both BALB/c and DBA/2 mice immunized with IFA/SLA. This cytokine may support the establishment of a Th2 response in these mice. Therefore it is suggested that Th2 cytokines play different roles between priming and maintaining the Th2 immune response after the infection.
Nashed
B F
BF
Department of Parasitology and Immunology, The University of Tokushima School of Medicine, Kuramoto-cho 3, 770-8503, Tokushima, Japan.
Maekawa
Y
Y
Takashima
M
M
Zhang
T
T
Ishii
K
K
Dainichi
T
T
Ishikawa
H
H
Sakai
T
T
Hisaeda
H
H
Himeno
K
K
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology*; D005260:Female; D005620:Freund's Adjuvant / Q000008:administration & dosage / Q000276:immunology; D007117:Immunization, Secondary; D016906:Interleukin-9 / Q000096:biosynthesis / Q000276:immunology; D007700:Kinetics; D018320:Leishmania major / Q000276:immunology*; D007896:Leishmaniasis / Q000276:immunology* / Q000469:parasitology; D008055:Lipids; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; D016906:Interleukin-9; D008055:Lipids; C114843:incomplete Freund's adjuvant; D005620:Freund's Adjuvant